Published in Law and Health Weekly, December 1st, 2007
Dalton Medicinal Chemistry will utilize their proprietary insights to design and synthesize several novel classes of compounds against selected RiboSwitch targets. BioRelix will advance these compounds using their cutting edge battery of biological assays and thorough knowledge of RiboSwitch drug discovery and development.
Brian Dixon, BioRelix CEO commented: "We are pleased to have the opportunity to work with the creative team at Dalton Medicinal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly